Table 3 Representative nanomedicines in clinical trials for treating ocular diseases
From: Nanotechnology-based ocular drug delivery systems: recent advances and future prospects
Products/Drugs | Nanoformulation | Indications | Trials | Phase |
|---|---|---|---|---|
Cyclosporine OTX-101 | Nanomicelles | Dry eye disease | NCT02845674 | III |
AXR-159 ophthalmic | Micelles | Dry eye disease | NCT03598699 | II |
ISV-303 | Micelles | Post cataract surgery inflammation | NCT01576952 | III |
ISV-305 | Micelles | Post cataract surgery inflammation | NCT03192137 | III |
Dexamethasone (OCS-01) | Nanoparticles | Inflammation, corneal pain | NCT04130802 | II |
Urea (Pluronic® F-127) | Nanoparticles | Cataracts | NCT03001466 | II |
Paclitaxel | Nanoparticles | Intraocular melanoma | NCT00738361 | II |
Liposomal latanoprost | Nanoparticles | Ocular hypertension | NCT01987323 | I/II |
SeeQ CdSe 655 | Nanoparticles | Retinitis pigmentosa | NCT04008771 | NA |
Dexamethasone (Cyclodextrin NP) | Nanoparticles | Diabetic macular edema | NCT01523314 | II/III |
GB-102 | Microparticles | Wet AMD | NCT03953079 | II |
Dexamethasone cyclodextrin | Microparticles | Diabetic macular edema | NCT01523314 | II |
Brimonidine tartrate | Nanoemulsion | Cataract | NCT04246801 | III |
Clobetasol propionate | Nanoemulsion | Graft-vs Host disease (oGVHD) | NCT03591874 | III |
OCU-310 | Nanoemulsion | Meibomian gland dysfunction | NCT03785340 | III |
TJO-087 | Nanoemulsion | Dry eye disease | NCT05245604 | III |
Catioprost | Nanoemulsion | Glaucoma | NCT01254370 | II |
Omega-3 Fatty acids (Remogen® Omega) | Microemulsion | Dry eye disease | NCT02908282 | NA |
Difluprednate (PRO-145) | Emulsion | Cataract | NCT03693989 | III |
KPI-121 (1% and 0.25% loteprednol etabonate) | Submicron suspension (PRINT technology) | Ocular infection, and inflammation | NCT00849537 | I, II |
KPI-121 (1% and 0.25% loteprednol etabonate) | Submicron suspension (PRINT technology) | Dry eye disease and keratoconjunctivitis sicca | NCT02163824 | III |
Triamcinolone | Microsphere | Diabetic macular edema | NCT02813265 | III |
D-4517.2 | Dendrimers | AMD | NCT05387837 | II |
TLC399 (Pro Dex) | Liposomes | Diabetic macular edema | NCT03093701 | II |
LAMELLEYE | Liposomes | Dry eye disease | NCT03140111 | NA |
Phospholipid (Artificial tears) | Liposomes | Dry eye disease | NCT02420834 | NA |
Liposomal latanoprost | Liposomes | Glaucoma | NCT01987323 | I/II |
Latanoprost (POLAT-001) | Liposomes | Ocular hypertension, open-angle glaucoma | NCT02466399 | II |
Hyaluronic acid | Liposomes | Meibomian gland dysfunction | NCT03617315 | NA |
Vincristine | Liposomes | Metastatic malignant uveal melanoma | NCT00506142 | II |
Marqibo | Liposomes | Retinoblastoma | NCT00335738 | III |
ENV 515 travoprost extended release (XR) | Intracameral implant (PRINT technology) | Glaucoma, ocular hypertension | NCT02371746 | II |
AR-1105 (dexamethasone) | Intravitreal implant | Macular edema | NCT03739593 | II |
AR-13503 | Intravitreal implant | Neovascular AMD, diabetic macular edema | NCT03835884 | I |